Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 9/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 3/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488129 | 0.87 | MAP3K14 (0.65) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL30554780 | 0.85 | MEN1 (0.45) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL21629023 | 0.85 | MEN1 (0.45) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL29488127 | 0.84 | CLK1 (0.52) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL29614769 | 0.81 | CLK1 (0.59) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL20691183 | 0.81 | CLK1 (0.71) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL30179272 | 0.79 | TDO2 (0.47) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL1612715 | 0.77 | CLK1 (0.73) | CLK1CDK5CDK5R1MAP3K14GSK3B | |
| SCHEMBL16205689 | 0.75 | CLK1 (0.51) | CLK1CDK5CDK5R1MAP3K14GSK3B | |
| SCHEMBL23175317 | 0.75 | GSK3B (0.71) | CLK1CDK5CDK5R1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | claimed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | claimed |
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2022-04-05 | — | — | US | claimed |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | FLT3, MCL1, CSF3R | CLK1 641/4885CDK5 845/4885CDK5R1 1910/4885 |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | FLT3, MCL1, CSF3R | CLK1 641/4885CDK5 845/4885CDK5R1 1910/4885 |
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | CLK1 3577/4885CDK5 438/4885CDK5R1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.